Neurocrine Biosciences, Inc. (NBIX) Reaches New 12-Month High at $57.69
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s share price reached a new 52-week high on Tuesday . The company traded as high as $57.69 and last traded at $57.72, with a volume of 420,628 shares traded. The stock had previously closed at $57.01.
A number of equities analysts have recently weighed in on the company. ValuEngine raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a research note on Friday. Piper Jaffray Companies set a $68.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Thursday, August 24th. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. Cowen and Company reaffirmed an “outperform” rating and issued a $65.00 price objective (up previously from $60.00) on shares of Neurocrine Biosciences in a research note on Wednesday, August 9th. Finally, BMO Capital Markets upped their price objective on Neurocrine Biosciences from $75.00 to $84.00 and gave the stock an “outperform” rating in a research note on Friday, August 4th. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $68.25.
The company’s 50-day moving average price is $51.39 and its 200 day moving average price is $48.00. The stock’s market capitalization is $5.12 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by $0.01. The business had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same period in the prior year, the business posted ($0.46) EPS. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.45) EPS for the current year.
In other news, insider Christopher Flint Obrien sold 8,734 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $50.00, for a total transaction of $436,700.00. Following the transaction, the insider now directly owns 57,707 shares in the company, valued at approximately $2,885,350. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Haig P. Bozigian sold 22,500 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $50.00, for a total value of $1,125,000.00. Following the transaction, the insider now owns 154,601 shares in the company, valued at $7,730,050. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,588 shares of company stock valued at $2,406,170. 4.80% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Neurocrine Biosciences by 7.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the last quarter. First Mercantile Trust Co. boosted its holdings in shares of Neurocrine Biosciences by 22.2% during the 1st quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after purchasing an additional 560 shares during the last quarter. ARS Investment Partners LLC acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $207,000. Stephens Inc. AR acquired a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $207,000. Finally, Capstone Asset Management Co. acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth approximately $214,000.
TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Reaches New 12-Month High at $57.69” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/05/neurocrine-biosciences-inc-nbix-reaches-new-12-month-high-at-57-69.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.